Literature DB >> 23771494

Incorporating process utility into quality adjusted life years: a systematic review of empirical studies.

Victoria K Brennan1, Simon Dixon.   

Abstract

OBJECTIVE: This review aimed to identify published studies that provide an empirical measure of process utility, which can be incorporated into estimates of QALY calculations.
METHODS: A literature search was conducted in PubMed to identify published studies of process utility. Articles were included if they were written in the English language and reported empirical measures of process utility that could be incorporated into the QALY calculation; those studies reporting utilities that were not anchored on a scale of 0 representing dead and 1 representing full health were excluded from the review.
RESULTS: Fifteen studies published between 1996 and 2012 were included. Studies included respondents from the USA, Australia, Scotland and the UK, Europe and Canada. Eight of the included studies explored process utility associated with treatments; six explored process utility associated with screening procedures or tests; and one was performed in preventative care. A variety of approaches were used to detect and measure process utility: four studies used standard gamble techniques; four studies used time trade-off (TTO); one study used conjoint analysis and one used a combination of conjoint analysis and TTO; one study used SF-36 data; one study used both TTO and EQ-5D; and three studies used wait trade-off techniques. Measures of process utility for different drug delivery methods ranged from 0.02 to 0.27. Utility estimates associated with different dosing strategies ranged from 0.005 to 0.09. Estimates for convenience (able to take on an empty stomach) ranged from 0.001 to 0.028. Estimates of process utility associated with screening and testing procedures ranged from 0.0005 to 0.031. Both of these estimates were obtained for management approaches to cervical cancer screening.
CONCLUSION: The identification of studies through conventional methods was difficult due to the lack of consistent indexing and terminology across studies; however, the evidence does support the existence of process utility in treatment, screening and preventative care settings. There was considerable variation between estimates. The range of methodological approaches used to identify and measure process utility, coupled with the need for further research into, for example, the application of estimates in economic models, means it is difficult to know whether these differences are a true reflection of the amount of process utility that enters into an individual's utility function, or whether they are associated with features of the studies' methodological design. Without further work, and a standardised approach to the methodology for the detection and measurement of process utility, comparisons between estimates are difficult. This literature review supports the existence of process utility and indicates that, despite the need for further research in the area, it could be an important component of an individual's utility function, which should at least be considered, if not incorporated, into cost-utility analyses.

Entities:  

Mesh:

Year:  2013        PMID: 23771494     DOI: 10.1007/s40273-013-0066-1

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  34 in total

1.  A comparison of preferences for two GLP-1 products--liraglutide and exenatide--for the treatment of type 2 diabetes.

Authors:  Michael Polster; Elaine Zanutto; Susan McDonald; Christopher Conner; Mette Hammer
Journal:  J Med Econ       Date:  2010-11-01       Impact factor: 2.448

2.  Should patients have a greater role in valuing health states?

Authors:  John Brazier; Ron Akehurst; Alan Brennan; Paul Dolan; Karl Claxton; Chris McCabe; Mark Sculpher; Aki Tsuchyia
Journal:  Appl Health Econ Health Policy       Date:  2005       Impact factor: 2.561

Review 3.  QALY league tables: handle with care.

Authors:  K Gerard; G Mooney
Journal:  Health Econ       Date:  1993-04       Impact factor: 3.046

4.  A cost utility analysis of treatment options for gallstone disease: methodological issues and results.

Authors:  J Cook; J Richardson; A Street
Journal:  Health Econ       Date:  1994 May-Jun       Impact factor: 3.046

5.  Incorporating societal concerns for fairness in numerical valuations of health programmes.

Authors:  E Nord; J L Pinto; J Richardson; P Menzel; P Ubel
Journal:  Health Econ       Date:  1999-02       Impact factor: 3.046

6.  Process utility in breast biopsy.

Authors:  J Shannon Swan; William F Lawrence; Jessica Roy
Journal:  Med Decis Making       Date:  2006 Jul-Aug       Impact factor: 2.583

7.  Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.

Authors:  Kristina S Boye; Louis S Matza; Kimberly N Walter; Kate Van Brunt; Andrew C Palsgrove; Aodan Tynan
Journal:  Eur J Health Econ       Date:  2010-03-12

8.  HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility?

Authors:  Kirsten Howard; Glenn Salkeld; Kirsten McCaffery; Les Irwig
Journal:  Health Econ       Date:  2008-05       Impact factor: 3.046

9.  Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens.

Authors:  Jeremy Chancellor; Samuel Aballéa; Alison Lawrence; Rob Sheldon; Sandrine Cure; Juliette Plun-Favreau; Nick Marchant
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

10.  Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study.

Authors:  Richard H Osborne; Richard De Abreu Lourenço; Andrew Dalton; Jennifer Houltram; David Dowton; Douglas Edgar Joshua; Robert Lindeman; Phoebe Joy Ho
Journal:  Value Health       Date:  2007 Nov-Dec       Impact factor: 5.725

View more
  24 in total

1.  Do Pills Have No Ills? Capturing the Impact of Direct Treatment Disutility.

Authors:  Alexander Thompson; Bruce Guthrie; Katherine Payne
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

Review 2.  Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence.

Authors:  Richard De Abreu Lourenco; Marion Haas; Jane Hall; Rosalie Viney
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

3.  Response to letter to editor: Capturing disutility from waiting time.

Authors:  Victoria K Brennan; Simon Dixon
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

4.  Capturing disutility from waiting time.

Authors:  Afschin Gandjour
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

5.  Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis.

Authors:  Natalie A Schwehr; Karen M Kuntz; Eva A Enns; Nathan D Shippee; Elaine Kingwell; Helen Tremlett; Adam F Carpenter; Mary Butler
Journal:  Drugs Aging       Date:  2020-03       Impact factor: 3.923

6.  OMERACT Quality-adjusted Life-years (QALY) Working Group: Do Current QALY Measures Capture What Matters to Patients?

Authors:  Logan Trenaman; Annelies Boonen; Francis Guillemin; Mickael Hiligsmann; Alison Hoens; Carlo Marra; Will Taylor; Jennifer Barton; Peter Tugwell; George Wells; Nick Bansback
Journal:  J Rheumatol       Date:  2017-03-15       Impact factor: 4.666

7.  Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis.

Authors:  George F Sawaya; Erinn Sanstead; Fernando Alarid-Escudero; Karen Smith-McCune; Steven E Gregorich; Michael J Silverberg; Wendy Leyden; Megan J Huchko; Miriam Kuppermann; Shalini Kulasingam
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873

8.  Patient Preferences for Pain Management in Advanced Cancer: Results from a Discrete Choice Experiment.

Authors:  David M Meads; John L O'Dwyer; Claire T Hulme; Phani Chintakayala; Karen Vinall-Collier; Michael I Bennett
Journal:  Patient       Date:  2017-10       Impact factor: 3.883

Review 9.  Conceptualising 'Benefits Beyond Health' in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis.

Authors:  Lidia Engel; Stirling Bryan; David G T Whitehurst
Journal:  Pharmacoeconomics       Date:  2021-08-23       Impact factor: 4.981

10.  Economic evaluation of process utility: elucidating preferences for a non-invasive procedure to treat restenosis.

Authors:  Maria V Aviles-Blanco
Journal:  Health Econ Rev       Date:  2021-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.